Baldness treatment co gets $5.5m:
This article was originally published in Clinica
Executive Summary
Follica, a Boston, Massachusetts firm developing a technology for treating hair loss caused by androgens in genetically susceptible men and women, has closed a $5.5m Series A financing round. The fundraising was led by Interwest Partners, and included the participation of existing investor PureTech Ventures participated. The new capital will take the company through a clinical proof-of-concept study. Follica's technology is designed to create and manipulate hair follicles in sufferers of androgenetic alopecia, a condition that affect around 50% of men and women in the US by the age of 50. The company said its technology can also be developed for treating other hair loss conditions and follicle-related disorders such as acne.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.